ArticleClinicoEconomics and outcomes research : CEOR2025
The HIV Epidemic in the United States - Epidemiological Projections and Public Economic Impact of Achieving Zero Transmission Goals.
Article in ClinicoEconomics and outcomes research : CEOR, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Ethical frameworks and community engagement in HIV cure-related research at the end of life: looking back, moving forward.Current opinion in HIV and AIDS · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The United States (US) HIV/AIDS strategy has targeted a 90% reduction in HIV infections by 2030. Whilst progress has been made in US HIV policy, the persistence of nearly 32,000 new infections annually highlights substantial barriers that still hinder effective treatment and the achievement of national targets. While the humanistic burden of HIV is well documented, there are broader economic effects on employment, disability and retirement. The objective of this study is to evaluate these economic gains when improving various HIV policies. Methodology: This analysis adapts a published Markov model assessing the role of six key policy parameters related to diagnosis, pre-exposure prophylaxis (PrEP) uptake, treatment initiation, and treatment as prevention (TasP) on the HIV epidemic in the US. Improvements in these parameters were explored to estimate averted HIV infections over 50 years and, subsequently, the feasibility of achieving the 2030 target of a 90% reduction in HIV incidence.A fiscal economic framework was also applied, linking HIV cases and policy targets to productivity, tax revenue, transfer benefits, and healthcare costs incurred by the US government. Results: Results were calculated for the general US population and for men who have sex with men (MSM), a subgroup experiencing a high HIV burden. For the general US population, policy improvements led to an average of 5,324 averted HIV infections annually over the 50-year horizon, corresponding to a total net annual fiscal gain of $397 million or $74,511 per averted infection. For the MSM subgroup, 911 infections were averted annually resulting in a net fiscal gain of $96 million, or $105,031 per averted infection. Conclusion: This analysis demonstrates that the benefits of HIV policy are not limited to the healthcare setting and show how initial investments provide long-term benefits by preventing HIV transmission and the associated impact on individuals' labor market outcomes. While relying on assumptions and projections that may not capture all real-word complexities, fiscal analyses can provide a useful tool for policy evaluation that facilitate a holistic assessment of the wider costs and benefits that fall on governments as well as benefits of achieving policy targets.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.